Insider Transactions in Q1 2021 at Standard Biotools Inc. (LAB)
Insider Transaction List (Q1 2021)
| Date | Insider | Transaction | Ownership Type | Shares Traded | Value / Price |
|---|---|---|---|---|---|
|
Mar 23
2021
|
Nicolas Barthelemy Director |
BUY
Exercise of conversion of derivative security
|
Indirect |
2,500
+1.47%
|
-
|
|
Mar 23
2021
|
Carlos V Paya Director |
BUY
Exercise of conversion of derivative security
|
Direct |
2,500
+4.05%
|
-
|
|
Feb 20
2021
|
Stephen Christopher Linthwaite President & CEO |
SELL
Payment of exercise price or tax liability
|
Direct |
57,705
-22.13%
|
$346,230
$6.12 P/Share
|
|
Feb 20
2021
|
Stephen Christopher Linthwaite President & CEO |
BUY
Grant, award, or other acquisition
|
Direct |
64,609
+19.86%
|
-
|
|
Feb 20
2021
|
Stephen Christopher Linthwaite President & CEO |
BUY
Exercise of conversion of derivative security
|
Direct |
48,750
+6.09%
|
-
|
|
Feb 20
2021
|
Colin Mc Cracken Chief Commercial Officer |
SELL
Payment of exercise price or tax liability
|
Direct |
7,872
-23.31%
|
$47,232
$6.12 P/Share
|
|
Feb 20
2021
|
Colin Mc Cracken Chief Commercial Officer |
BUY
Exercise of conversion of derivative security
|
Direct |
13,691
+12.76%
|
-
|
|
Feb 20
2021
|
Vikram Jog Chief Financial Officer |
SELL
Payment of exercise price or tax liability
|
Direct |
12,698
-12.71%
|
$76,188
$6.12 P/Share
|
|
Feb 20
2021
|
Vikram Jog Chief Financial Officer |
BUY
Grant, award, or other acquisition
|
Direct |
18,612
+15.7%
|
-
|
|
Feb 20
2021
|
Vikram Jog Chief Financial Officer |
BUY
Exercise of conversion of derivative security
|
Direct |
15,491
+4.7%
|
-
|
|
Feb 20
2021
|
Laura Clague Director |
BUY
Grant, award, or other acquisition
|
Direct |
9,803
+20.87%
|
-
|
|
Feb 20
2021
|
Bradley Allen Kreger SVP, Global Operations |
SELL
Payment of exercise price or tax liability
|
Direct |
6,122
-13.65%
|
$36,732
$6.12 P/Share
|
|
Feb 20
2021
|
Bradley Allen Kreger SVP, Global Operations |
BUY
Exercise of conversion of derivative security
|
Direct |
14,923
+10.72%
|
-
|